Details for Patent: 9,585,883

Which drugs does patent 9,585,883 protect, and when does it expire?

Patent 9,585,883 protects CAMZYOS and is included in one NDA.

This patent has sixty patent family members in thirty-seven countries.

Summary for Patent: 9,585,883

Scope and claims summary:

Title:	Pyrimidinedione compounds
Abstract:	Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.
Inventor(s):	Oslob; Johan (Sunnyvale, CA), Anderson; Robert (Brisbane, CA), Aubele; Danielle (San Mateo, CA), Evanchik; Marc (San Jose, CA), Fox; Jonathan Charles (San Francisco, CA), Kane; Brian (Oakland, CA), Lu; Puping (Foster City, CA), McDowell; Robert (San Francisco, CA), Rodriguez; Hector (Brisbane, CA), Song; Yonghong (Foster City, CA), Sran; Arvinder (Fremont, CA)
Assignee:	MYOKARDIA, INC. (South San Francisco, CA)
Application Number:	14/883,152
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,585,883

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-001	Apr 28, 2022		RX	Yes	No						TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-002	Apr 28, 2022		RX	Yes	Yes						TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-003	Apr 28, 2022		RX	Yes	No						TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS
Bristol	CAMZYOS	mavacamten	CAPSULE;ORAL	214998-004	Apr 28, 2022		RX	Yes	No						TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS

International Family Members for US Patent 9,585,883

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3010910		CR 2023 00034	Denmark
European Patent Office	3010910		301253	Netherlands
European Patent Office	3010910		PA2023535	Lithuania
European Patent Office	3010910		2023C/546	Belgium
European Patent Office	3010910		LUC00324	Luxembourg